Milestone Initiates ReVeRA-301 Phase 3 for AFib-RVR, Extending Etripamil Platform

What happened

Milestone Pharmaceuticals announced the initiation of ReVeRA-301, a pivotal Phase 3 trial evaluating etripamil nasal spray (the same 70 mg repeat-dose regimen approved for PSVT) for self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR). This marks a key milestone as the company had guided to first-patient enrollment in 2H26, and the trial start in August 2026 keeps that timeline on track. Using the already-approved dose and delivery method could streamline the development pathway, potentially allowing an sNDA rather than a full NDA if successful. However, trial initiation is only the first step; AFib-RVR is a distinct indication with different patient characteristics and endpoints, and Phase 3 failure risk remains material. The announcement extends Milestone's etripamil franchise beyond PSVT, but the core commercial challenge remains CARDAMYST's weak revenue conversion and heavy gross-to-net deductions in its initial launch.

Implication

The initiation of ReVeRA-301 confirms execution on the pipeline and provides a near-term catalyst, but it does not de-risk the company's fundamental commercial challenges. The trial will take years to complete, and even if successful, AFib-RVR is a broader indication that could expand the market, but Milestone's balance sheet constraints and royalty obligations mean near-term dilution risk persists. Investors should continue to prioritize monitoring CARDAMYST's net revenue per script and payer coverage expansion, as those are the most direct drivers of value over the next 6-12 months. The AFib-RVR program adds optionality, but it also increases cash burn, and the company's runway into 2H27 may be consumed faster if both launch and trial costs accelerate. Any positive news from the trial initiation may provide a short-term bounce, but the stock is likely to remain range-bound until clearer commercial traction is demonstrated.

Thesis delta

The initiation of ReVeRA-301 shifts the pipeline narrative from planned to in-progress, confirming management's timeline and adding a second potential indication for etripamil. However, this does not alter the near-term investment thesis, which remains centered on CARDAMYST's ability to convert broad prescriber adoption into clean net revenue. The WAIT rating stands: the stock still requires evidence of improved gross-to-net conversion and no ATM usage before becoming attractive.